Metastatic Paraganglioma of the Spine With SDHB Mutation: Case Report and Review of the Literature
The International Journal of Spine Surgery2021Vol. 14(s4), pp. S37–S45
Citations Over Time
Rashad Jabarkheel, Arjun V. Pendharkar, Jonathan Lavezo, Justin P. Annes, Kaniksha Desai, Hannes Vogel, Atman Desai
Abstract
Patients with SDHx mutation, particularly SDHB, have increased risk of developing metastatic PGLs. Consequently, these individuals require long-term surveillance given the risk for developing new tumors or disease recurrence, even years to decades after primary tumor resection. Surgical management of spinal metastatic PGL involves correcting spinal instability, minimizing tumor burden, and alleviating epidural cord compression. In patients with metastatic PGL of the spine, genetic testing should be considered.
Related Papers
- → Early-Onset Renal Cell Carcinoma as a Novel Extraparaganglial Component of SDHB-Associated Heritable Paraganglioma(2004)387 cited
- → SDHAF2 mutations in familial and sporadic paraganglioma and phaeochromocytoma(2010)269 cited
- → Carbonic anhydrase 9 immunohistochemistry as a tool to predict or validate germline and somatic VHL mutations in pheochromocytoma and paraganglioma—a retrospective and prospective study(2019)46 cited
- → Cervical paragangliomas: is SDH genetic analysis systematically required?(2007)33 cited
- → Germline mutations and genotype–phenotype correlations in patients with apparently sporadic pheochromocytoma/paraganglioma in Korea(2013)23 cited